CAPTRUST Financial Advisors
TRAW icon

CAPTRUST Financial Advisors’s Traws Pharma TRAW Stock Holding History

CAPTRUST Financial Advisors’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-267
Closed -$59K – 3270
2020
Q2 		$59K Buy
+267
New +$40.8K ﹤0.01% 1559

Other funds holding TRAW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
QP
Quilter Plc London, United Kingdom $5.7B AUM 21.25% 1-Year Est. Return

CAPTRUST Financial Advisors's TRAW Position: Q3 2020 in Review

CAPTRUST Financial Advisors sold out of Traws Pharma (TRAW) in Q3 2020, closing a stake of 267 shares — an estimated $59K sold.

CAPTRUST Financial Advisors first reported a position in TRAW in Q2 2020 and held it in 1 quarter. The position peaked at $59K in Q2 2020. 30 funds tracked by Wall St. Rank hold TRAW as of Q3 2020.

  • CAPTRUST Financial Advisors reported no remaining Traws Pharma position as of Q3 2020 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 267 Traws Pharma shares in Q3 2020, an estimated $59K.
  • CAPTRUST Financial Advisors first reported a position in Traws Pharma in Q2 2020 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Traws Pharma position peaked at $59K in Q2 2020.
  • 30 funds tracked by Wall St. Rank held Traws Pharma as of Q3 2020.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2020, filed 17 Nov 2020.